Richard Giltner, a director at United Therapeutics Corp (NASDAQ:UTHR), recently executed a series of stock transactions, according to a filing with the Securities and Exchange Commission. On November 5, Giltner sold a total of 10,000 shares of common stock, generating approximately $3.8 million. The sales were conducted at prices ranging from $381.6065 to $382.2762 per share.
Additionally, Giltner exercised stock options to acquire 10,000 shares at a price of $175.43 per share. Following these transactions, Giltner's direct ownership of United Therapeutics stands at 17,420 shares.
In other recent news, United Therapeutics reported a significant increase in its third-quarter revenue for 2024, reaching $748.9 million, primarily due to the heightened sales of treprostinil-based products. Ladenburg Thalmann maintained a neutral rating on the company's stock, while raising the price target to $344. H.C. Wainwright reaffirmed a buy rating and increased the price target to $425, reflecting a positive outlook on the company's strategic positioning and Tyvaso's strong performance.
United Therapeutics has been proactive in securing its market share by initiating contracts with Part D payers, a move not historically typical for the company's product Tyvaso. The company also completed a $1 billion accelerated share repurchase program and is eyeing upcoming clinical milestones, including the TETON 2 study results, and is awaiting a potential FDA decision on its Centralized Lung Evaluation System in 2025.
Despite a slight decrease in worldwide revenue for Remodulin, the company is confident in its long-term viability as a preferred treatment for pulmonary arterial hypertension. These are among the recent developments at United Therapeutics, as the company continues to focus on expanding commercial ventures and research and development.
InvestingPro Insights
United Therapeutics Corp (NASDAQ:UTHR) has been demonstrating strong financial performance, which aligns with Director Richard Giltner's recent stock transactions. According to InvestingPro data, the company's revenue growth stands at an impressive 25.04% for the last twelve months as of Q3 2024, with a robust gross profit margin of 88.94%. This financial strength is further reflected in the stock's performance, with a 67.75% price total return over the past year.
InvestingPro Tips highlight that United Therapeutics has been aggressively buying back shares, which could be seen as a vote of confidence from management in the company's future prospects. Additionally, the company holds more cash than debt on its balance sheet, indicating a strong financial position that may support future growth initiatives or weather potential market uncertainties.
The stock's recent performance is particularly noteworthy, with InvestingPro data showing a 46.93% price total return over the past six months. This upward trajectory is supported by the company's impressive gross profit margins and its trading near its 52-week high, as noted in the InvestingPro Tips.
For investors seeking a more comprehensive analysis, InvestingPro offers 16 additional tips for United Therapeutics, providing a deeper understanding of the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.